Human Genetics and Genomics for Drug Target Identification and Prioritization: Open Targets' Perspective.

Area of Science:

• Genomics and Bioinformatics
• Drug Discovery and Development
• Human Genetics

Background:

• The Open Targets consortium integrates academic and industry expertise.
• Leveraging human genetics and genomics is crucial for understanding disease mechanisms.
• Systematic evidence integration is needed for effective target identification.

Purpose of the Study:

• To outline the Open Targets approach for generating therapeutic hypotheses.
• To highlight the role of human genetics and genomics in drug discovery.
• To present the platform's capabilities in target prioritization.

Main Methods:

• Utilizing a locus-to-gene machine learning model with data from genome-wide association studies (GWAS), functional genomics, and epigenetics.
• Integrating diverse genetic evidence including gene burden analyses, rare disease genetics, somatic mutations, and perturbation assays.
• Employing open-source informatic platforms to systematically build and score target-disease associations.

Main Results:

• The Open Targets platform systematically integrates multi-omics data to build target-disease associations.
• A machine learning model predicts potential drug targets for complex diseases.
• Target attributes like clinical precedence, tractability, and safety are scored to guide prioritization.

Conclusions:

• Human genetics and genomics are invaluable for generating robust therapeutic hypotheses.
• The Open Targets platform provides a dynamic and systematic approach to target discovery.
• This integrated strategy accelerates the identification of promising drug targets.